Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Rivian Automotive, Inc. (RIVN) Price & Performance

BioNano Genomics IncTrade
Rivian Automotive, Inc.Trade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Rivian Automotive, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Rivian Automotive, Inc. trades at $17.8 (market cap $25.33B). The key difference: Rivian Automotive, Inc. is far larger — about 1918.9× BioNano Genomics Inc's market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGORIVN
Market Cap
$13.20M$25.33B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$22.45
52-Week Low
$1.09$11.64
Enterprise Value
$15.81M$27.07B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Rivian Automotive, Inc.

Rivian Automotive (RIVN) trades at $17.31, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $19.22. The company has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -63.62%. Recent news highlights the potential of the R2 vehicle launch and a $1.74 billion stock offering to fund expansion, creating mixed investor sentiment amid growth prospects and dilution concerns.

The outlook hinges on R2 success and path to profitability, offering upside if execution improves, but high cash burn, competitive pressures, and shareholder dilution present significant risks. Analyst consensus is cautiously optimistic with 44.83% buy ratings, but the stock faces volatility around earnings and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN